Piper Sandler Maintains Neutral on NextGen Healthcare, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan maintains a Neutral rating on NextGen Healthcare (NASDAQ:NXGN) and lowers the price target from $20 to $17.
May 18, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler analyst maintains Neutral rating on NextGen Healthcare (NASDAQ:NXGN) and lowers price target from $20 to $17.
The news directly mentions NextGen Healthcare (NASDAQ:NXGN) and the lowered price target by Piper Sandler analyst Jessica Tassan. This may cause some uncertainty among investors, but the Neutral rating suggests that the stock is not expected to have significant short-term price movement. The lowered price target may have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100